PMID- 11095412
OWN - NLM
STAT- MEDLINE
DCOM- 20010308
LR  - 20191025
IS  - 0960-8931 (Print)
IS  - 0960-8931 (Linking)
VI  - 10
IP  - 5
DP  - 2000 Oct
TI  - TYRP2-mediated resistance to cis-diamminedichloroplatinum (II) in human melanoma 
      cells is independent of tyrosinase and TYRP1 expression and melanin content.
PG  - 499-505
AB  - Tyrosinase-related protein-2 (TYRP2) is a melanocyte-specific enzyme that 
      catalyses the non-decarboxylative tautomerization of L-dopachrome to 
      5,6-dihydroxyindole-2-carboxylic acid (DHICA) in the melanin biosynthetic 
      pathway. We have recently demonstrated that the constitutive expression of TYRP2 
      in human melanoma cells positively correlates with cis-diamminedichloroplatinum 
      (II) (CDDP) resistance, and that the ectopic expression of TYRP2 in 
      CDDP-sensitive cells rendered them more resistant to CDDP treatment. Here, we 
      demonstrate that this correlation between constitutive TYRP2 expression and CDDP 
      resistance applies to a panel of distinct human melanoma cell lines obtained from 
      patients with melanoma at various stages of disease progression. We further show 
      that CDDP resistance correlates only with TYRP2 expression and is associated 
      neither with tyrosinase and TYRP1 expression, nor with cellular melanin content. 
      Together, these results further support the notion that TYRP2 is a novel mediator 
      of CDDP resistance in melanoma cells and suggest that this function of TYRP2 is 
      independent of cellular melanin content and of the other regulatory enzymes of 
      the melanogenic pathway.
FAU - Pak, B J
AU  - Pak BJ
AD  - Sunnybrook and Women's College Health Sciences Centre and Toronto Sunnybrook 
      Regional Cancer Centre, Division of Cancer Biology Research, Ontario, Canada.
FAU - Li, Q
AU  - Li Q
FAU - Kerbel, R S
AU  - Kerbel RS
FAU - Ben-David, Y
AU  - Ben-David Y
LA  - eng
GR  - CA-41233/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Melanins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Proteins)
RN  - EC 1.- (Oxidoreductases)
RN  - EC 1.14.18.- (TYRP1 protein, human)
RN  - EC 1.14.18.- (tyrosinase-related protein-1)
RN  - EC 1.14.18.1 (Monophenol Monooxygenase)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.3.12 (dopachrome isomerase)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Cell Survival/drug effects
MH  - Cisplatin/*toxicity
MH  - *Drug Resistance, Neoplasm
MH  - Gene Expression Regulation, Enzymologic
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Intramolecular Oxidoreductases/*genetics/metabolism
MH  - Melanins/*metabolism
MH  - Melanoma
MH  - *Membrane Glycoproteins
MH  - Monophenol Monooxygenase/genetics
MH  - *Oxidoreductases
MH  - Proteins/genetics
MH  - Tumor Cells, Cultured
EDAT- 2000/11/30 11:00
MHDA- 2001/03/10 10:01
CRDT- 2000/11/30 11:00
PHST- 2000/11/30 11:00 [pubmed]
PHST- 2001/03/10 10:01 [medline]
PHST- 2000/11/30 11:00 [entrez]
AID - 10.1097/00008390-200010000-00013 [doi]
PST - ppublish
SO  - Melanoma Res. 2000 Oct;10(5):499-505. doi: 10.1097/00008390-200010000-00013.